株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

市場アクセスの影響力:メラノーマ (米国)

Market Access Impact: Melanoma (US) 2018

発行 FirstWord 商品コード 488061
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
詳細については [見積・お問合せ] ボタンよりお問い合わせ下さい。
Back to Top
市場アクセスの影響力:メラノーマ (米国) Market Access Impact: Melanoma (US) 2018
出版日: 2018年02月01日 ページ情報: 英文
概要

米国では、メラノーマ治療薬の主要ブランドのうち1/5近くが、市場の何等かの障害による影響を受けていますが、特に価格面・市場アクセスの2つが強い影響力を及ぼしています。その結果、主要ブランド薬8種のうち、1社は大きく、3社は多少はシェアを伸ばしていますが、2社はシェアを大きく減らしています。

当レポートでは、米国の癌専門医・皮膚癌専門医100名を対象に、メラノーマ治療薬の主要ブランド (全8種) の処方傾向に対する、市場の各種障害の影響度について調査し、市場の障害の概略 (全7項目:価格、市場アクセス) や、それがブランド別市場シェアや医師の医薬品選択に及ぼす影響度などを分析しております。

調査課題

  • 各種障壁の市場アクセスに対する影響
    • 医師がもっとも多く処方するブランドは?
    • 各種障壁の影響を受ける処方箋の数は?
    • どの障壁がもっとも影響が大きいか?
  • 各種障壁の各ブランドへの影響
    • 各ブランドを処方する医師の数は? 処方していないが、検討するつもりの数は?
    • 処方しない理由は?その代わりに処方しているものは?
    • 各ブランドの市場シェアは?

調査対象

  • Cotellic (コビメチニブ:Roche)
  • Imlygic (タリモジーン・ラハーパレプベック:Amgen)
  • Keytruda (ペンブロリズマブ:Merck & Co.)
  • Mekinist (トラメチニブ:Novartis)
  • Opdivo (ニボルマブ:Bristol-Myers Squibb)
  • Tafinlar (ダブラフェニブ:Novartis)
  • Yervoy (イピリムマブ:Bristol-Myers Squibb)
  • Zelboraf (ベムラフェニブ:Roche)

目次

第1章 市場障壁とは

第2章 本レポートについて

第3章 本調査について

第4章 調査に含まれるブランド

第5章 エグゼクティブサマリー

目次

Market barriers affect just under a fifth of melanoma prescriptions. Is your brand losing out?

In the US, where market barriers affect just under a fifth of all melanoma prescriptions, the top brand has a significant lead over all other brands. Find out what's driving its share gains, and what your brand can do to level the playing field in Market Access Impact: Melanoma (US) [2018].

Based on a survey of 100 oncologists and dermato-oncologists, the report covers 8 major therapies from Amgen, Bristol-Myers Squibb, Merck & Co., Novartis, and Roche. Handy graphs and charts reveal which of the 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.

Top Takeaways

  • Barriers affect just under a fifth of all prescriptions: But cost and market access barriers affect more prescriptions than all others barriers combined.
  • Only one brand sees a significant share increase: Four brands gain share thanks to barriers, but the top-gaining brand sees a much bigger bump than the other three.
  • Two brands see significant losses: The two least prescribed brands each lose nearly 2% of their market share because of barriers.
  • Eliminating barriers would nudge two brands up in the rankings: the third-place brand would move up to second place and the eighth-place brand would edge out "other" brands' aggregate score.
  • Only half of the surveyed brands are widely prescribed: More than 70% of surveyed doctors prescribe the top four brands, but only 30-60% prescribe the bottom three.
  • Three brands have perception problems: Up to nearly 20% of surveyed doctors either would not prescribe, or are not aware of these brands.

Insight into 8 Major Melanoma Drugs

  • Cotellic (cobimetinib; Roche)
  • Imlygic (talimogene laherparepvec; Amgen)
  • Keytruda (pembrolizumab; Merck & Co.)
  • Mekinist (trametinib; Novartis)
  • Opdivo (nivolumab; Bristol-Myers Squibb)
  • Tafinlar (dabrafenib; Novartis)
  • Yervoy (ipilimumab; Bristol-Myers Squibb)
  • Zelboraf (vemurafenib; Roche)

Market Access Impact: Melanoma (US) [2018] explores key issues affecting melanoma drug manufacturers. You'll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest impact?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don't, but would consider it?
  • Why don't doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 100 US-based medical oncologists and dermato-oncologists, chosen from the largest community of validated physicians in the world. All respondents have:P5

All respondents:

  • Have been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients in total in the last month

We conducted the survey between January 10-23, 2018.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

Table of Contents

1. What are market barriers?

2. About this report

3. About the survey

4. Brands included in the survey

5. Executive summary

Back to Top